IMGN News and Press, ImmunoGen Inc. From 11/06/20

Image source: The Motley Fool. Immunogen Inc (NASDAQ: IMGN) Q3 2020 Earnings Call Nov 6, 2020 , 8:00 a.m. ET Operator Continue reading For further details see: Immunogen Inc (IMGN) Q3 2020 Earnings Call Transcript

ImmunoGen ([[IMGN]]) Q3 results:Revenues: $18.2M (+36.8%); non-cash royalty revenue: $18.1M (+37.1%).Net loss: ($22.4M) (-2.8%); loss/share: ($0.13) (+13.3%).2020 guidance: Revenues: $60M - 65M (unch) (consensus: $67.37M); operating expenses: $160M - 165M from $165M - 170M; cash and equivalen...

ImmunoGen (IMGN): Q3 GAAP EPS of -$0.13 beats by $0.06.Revenue of $18.19M (+37.0% Y/Y) beats by $2.96M.The company has updated its financial guidance for 2020 as follows:revenues between $60 million and $65 million vs. $67.37M;operating expenses between $160 million and $165 million;cash and ...

Partnership with Huadong Medicine Accelerates Development and Commercialization of Mirvetuximab Soravtansine in Greater China Encouraging Anti-Tumor Activity and Tolerability Data from FORWARD II Triplet Cohort Evaluating Mirvetuximab in Combination with Carboplatin and Av...

ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller, Chief Financial Officer, and Anna Berkenblit, Chief Medical Officer, will participate in a fireside chat at the u...

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, November 6, 2020 to discuss its third quarter operating results. Ma...

ImmunoGen ([[IMGN]] -0.9%) has agreed to partner with Huadong Medicine Co., Ltd. subsidiary Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize mirvetuximab soravtansine in Greater China (mainland, Hong Kong, Macau and Taiwan).Under the terms of the deal, IMGN will...

Partnership Accelerates Development Path for Mirvetuximab in Greater China and Expands Huadong Medicine’s Oncology Portfolio with Innovative ADC Combines ImmunoGen’s Lead Clinical Program with Huadong’s Regional Oncology Expertise ImmunoGen to Rece...

ImmunoGen (IMGN) has raised gross proceeds of ~$54.8M through its At-the-Market ((ATM)) facility pursuant to its Open Market Sale Agreement dated as of September 25 with Jefferies. On October 9, the Company sold ~12.7M common shares at $4.33.The additional funds raised through ...

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that it has raised gross proceeds of approximately $54.8 million through its At-the-Market (“ATM") facility pursuant to its Open Market ...